FSA CBD product list brings clarity to the sector

By Gwen Ridler contact

- Last updated on GMT

The FSA's list of credible CBD products could create confidence for investors and brings clarity to manufacturers
The FSA's list of credible CBD products could create confidence for investors and brings clarity to manufacturers

Related tags: CBD and Hemp, cannabidiol

Producers of food and drink products containing cannabidiol (CBD) have been provided with clarity over the future legality of their products on the UK market, as the Food Standards Agency (FSA) published its list of credible Novel Foods applications.

On 31 March, the FSA published a list of more than 3,500 products containing CBD that had a credible application for authorisation as Novel Foods.  

The group emphasised that it did not endorse the products on the list and that inclusion on the list did not guarantee that they would be authorised as they had not yet been fully assessed for safety.  

Emily Miles, FSA chief executive, said: “We have taken the step of publishing the list so that local authorities, retailers and consumers can make informed judgments about what they stock and buy, as we gradually bring this growing market into compliance with the law.” 

Representing the industry  

The Association for the Cannabinoid Industry (ACI) welcomed the publication of the list. The group's members accounted for about 64% of the applications made to the FSA since its consultation in CBD products was launched in 2020.

Steve Moore, ACI founder, commented: The FSA public list represents a major milestone for the UK’s CBD category. It demonstrates the progress the sector has made to meet compliance requirements and creates greater regulatory certainty which, in turn, will increase levels of consumer trust, encourage investment in the sector, and promote innovation.

“Obviously there are casualties today. There are a large number of high-profile products that have not made the list and are now subject to enforcement.”  

“From a business perspective there’s an excitement about the potential for investment in this category and the innovation that will support in the coming years. We now have a new category that will continue to invest in regulatory process, but also the innovation process and there’s a symbiotic link between the two."

ACI predicted investment in CBD novel foods would increase at the end of 2023, once authorisation for the products on the FSA list started to trickle through.  

Regulation progress  

Adam Pritchard, chief commercial officer of Love Hemp, said: “We note the latest update from the FSA and are delighted with the results. The CBD industry in the UK has been largely unregulated, resulting in a lack of clarity for our consumers, and we welcome progress made to date by the FSA. 

“We continue to work closely with the FSA and look forward to the next stage of the process, proceeding to validation followed by full approvals.” 

Tim Clarke, managing director of Cannaray CBD, said Novel Foods regulation for CBD would allow the market in the UK to reach its full potential by ensuring rigorous standards of product safety and quality across the full CBD market. 

He added: “Regulation by the FSA is creating a step-change in the quality and safety of the overall CBD market, such that shoppers can try CBD in confidence, and manufacturers and retailers can partner together to accelerate category growth.” 

Critical response  

However, others were more critical of the FSA’s decision to authorise the sale of CBD products in the UK.  

David Hardstaff of the Cannabis Regulatory team at BCL Solicitors said: "The FSA’s claim that creating a public list would help local authorities and retailers to prioritise products to be removed from sale fails to recognise the complexity and scale of the UK’s now mature CBD market.​ 

“CBD products are widely available in retail stores and online in the form of oils, drops, gels, confectionery, cakes, biscuits and drinks,​” he continued. 

“The FSA list shows products that have a ‘credible application’ which can be authorised as the FSA expects to receive significant scientific evidence that it is safe. Those not listed, the FSA expects local authorities and retailers should remove from sale.” 


Related news

Show more


Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.